Oxford FemTech Society’s Post

#Biomarkers and #sensors in cancer therapy are crucial for the diagnosis, prognosis, and treatment monitoring of various cancers. They play a key role in personalized medicine, allowing for tailored therapies based on the unique characteristics of a patient’s tumor. Here’s an overview of their significance and applications: #Biomarkers in Cancer Therapy Biomarkers are biological molecules found in blood, other body fluids, or tissues that can be a sign of a normal or abnormal process, or of a condition or disease, such as cancer. In cancer therapy, biomarkers are used for: 1. Diagnosis and Early Detection: • Tumor-specific Antigens: Proteins like PSA (Prostate-Specific Antigen) for prostate cancer and CA-125 for ovarian cancer. • Genetic Markers: Mutations in genes like BRCA1/BRCA2 for breast and ovarian cancer. 2. Prognosis: • Gene Expression Profiles: Tools like Oncotype DX for breast cancer predict the likelihood of cancer recurrence and the potential benefit from chemotherapy. • Circulating Tumor DNA (ctDNA): Offers insights into tumor dynamics and can predict disease progression. 3. Predictive Biomarkers: • PD-L1 Expression: Used to predict response to immunotherapies in cancers like melanoma and non-small cell lung cancer. • EGFR Mutations: Targeted therapies for non-small cell lung cancer rely on the presence of specific mutations in the EGFR gene. 4. Monitoring and Disease Surveillance: • Liquid Biopsies: Non-invasive tests using ctDNA to monitor treatment response and detect minimal residual disease (MRD). • Tumor Markers: Regular monitoring of markers like CEA for colorectal cancer or AFP for liver cancer to track disease status. #Sensors in Cancer Therapy Sensors in cancer therapy are technologies designed to detect and measure biological, chemical, or physical signals that are indicative of cancerous activity. They enable real-time monitoring of the patient’s condition and the efficacy of treatments. Some applications include: 1. Biosensors: • Electrochemical Sensors: Detect specific biomolecules such as DNA sequences, proteins, or metabolites that are indicative of cancer. • Optical Sensors: Use light to detect changes in tissues, such as fluorescence-based detection of tumor-specific markers. 2. Wearable Sensors: • Smart Devices: Wearable devices can monitor vital signs, physical activity, and drug intake, providing continuous data that can be analyzed to assess a patient’s response to treatment. • Implantable Sensors: Devices like the Oxi-Alert system can be implanted to monitor oxygen levels in tumor tissues, providing real-time data on the tumor environment. 3. Imaging Sensors: • MRI and PET Scans: Enhanced with molecular imaging agents that target specific biomarkers, allowing for more precise tumor imaging and monitoring of therapeutic response. • Nanosensors: Nanoparticle-based sensors that can circulate in the body, targeting and highlighting tumor cells for imaging and targeted therapy.

🧬 Ivana Domljanovic is tackling the limitations of mammography screenings for breast cancer by inventing a DNA origami nanosensor! 💡   🔍 This innovative technology offers:   🔹Rapid, accurate, and safe screenings 🕒🎯 🔹Cost-effective solutions for early detection 💸💖 🧬 The nanosensor detects breast cancer in its early stages by measuring circulating miRNA biomarkers 🔬. With this breakthrough, there's potential to:  🔹Advance molecular diagnostics 🧠 🔹Expand to detect other cancers and diseases in the future 🌍 https://lnkd.in/e4RQkgj3   #BreastCancerAwareness #EarlyDetection #WomenInSTEM #MedicalInnovation #Nanotechnology #DNAScience #HealthcareInnovation #CancerResearch #MolecularDiagnostics #Biotech #TechForGood #FutureOfMedicine #ScreeningTech #HealthTech #miRNA #SafeScreening #CancerScreening #InnovativeSolutions #PrecisionMedicine #Pharma #Oncology   @PfizerOncology @Roche @Novartis @AstraZeneca @MerckGroup @Sanofi @Amgen @BristolMyersSquibb @JanssenGlobal @GileadSciences @Genentech @EliLillyCo @AbbVie @TakedaPharma

It’s a critical time to catch up on what’s new in breast imaging, especially in light of the new FDA mandate (going into effect in late 2024) that will open new options for women with dense breast to finally start to be treated differently. How so? The door will open to conversations about supplemental screening that actually works and can transform sensitivity to above 90% for small tumors in dense breast. It’s time!

Join us for a deep dive into the world of cancer imaging with #EUCAIM’s webinar on March 14. You will be able to learn more about the EUCAIM project, explore the Cancer Image Europe Platform first-hand, and get insights into EUCAIM’s Open Call launching in April 2024. EUCAIM’s Platform is the cornerstone of the European Cancer Imaging Initiative. As one of the flagships of Europe’s Beating Cancer Plan, the Initiative aims to foster innovation and deployment of digital technologies, including AI tools, to achieve better treatment and care for cancer patients.  #EUCAIM #DigitalEU #EUCancerImaging #EUCancerPlan

Check out this recent paper on cervical cancer, published by some of Biorbyt's partners. https://lnkd.in/ekVepbYi #research #cancer #laboratory #lifeciences

Hello Everyone , Today I am sharing my new project of Machine learning. In which I find a real-world application/use of  KNN and Illustrate the the idea of the algorithm by using the example. The real world application is Breast Cancer Prediction Using K-Nearest Neighbors (KNN) , go through my project as I explained KNN in my first few slides and then the application. Feel free to check out my project in detail here: https://lnkd.in/eXhfgppp #KNN #Project

Great example of another technology integration : Integrating in situ proximity ligation assay Navinci Diagnostics for PD1-PDL1 interaction with multiplexed immunofluorescence imaging on #PhenoCyclerFusion Akoya Biosciences, Inc. #urothelialcarcinoma #spatialproteomics #singlecellresolution #spatialprofiling

A comprehensive state-of-the-science review of MSCs in cancer, focusing on the role of MSCs in the formation of the tumor microenvironment, known tumor supportive functions, and areas for further research. https://lnkd.in/epJnjHYc

'In Figure 2 we illustrate the hallmarks of cancer engineering by arranging 12 cardinal fields around a tumor, and in the sections below we provide brief introductions to these fields.' https://lnkd.in/dRxzTkhE

The EACR's Highlights in Cancer Research picks out key recent papers so you don't have to 💡 Discover why we selected this Cancer Discovery paper by Wang, Z. et al.: https://lnkd.in/eTuCfH9B